Altimmune (ALT) Debt to Equity (2012 - 2026)
Altimmune (ALT) reported Debt to Equity of $0.12 for Q1 2026, down 20.31% on a QoQ basis from $0.15 in Q4 2025.
Altimmune (ALT) has 14 years of Debt to Equity data on file, last reported at $0.12 in Q1 2026.
- Quarterly Debt to Equity changed N/A year-over-year to $0.12 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $0.12 (changed N/A YoY) and the FY2025 annual result came in at $0.15, changed N/A from the prior year.
- Debt to Equity declined to $0.12 in Q1 2026 per ALT's latest filing, from $0.15 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.15 in Q4 2025 and bottomed at $0.01 in Q2 2022.
- The 4-year median for Debt to Equity is $0.03 (2023), against an average of $0.06.
- Peak annual rise in Debt to Equity reached 363.46% in 2022, while the deepest fall reached 34.74% in 2022.
- Tracing ALT's Debt to Equity over 4 years: stood at $0.02 in 2022, then advanced by 15.78% to $0.03 in 2023, then surged by 432.62% to $0.15 in 2025, then fell by 20.31% to $0.12 in 2026.
- Per Business Quant, the three latest ALT Debt to Equity figures stand at $0.12 (Q1 2026), $0.15 (Q4 2025), and $0.08 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.06 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | 0.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.12 |
| Dec 31, 2025 | 0.15 |
| Sep 30, 2025 | 0.08 |
| Jun 30, 2025 | 0.09 |
| Sep 30, 2023 | 0.03 |
| Jun 30, 2023 | 0.02 |
| Mar 31, 2023 | 0.03 |
| Dec 31, 2022 | 0.02 |
| Sep 30, 2022 | 0.02 |
| Jun 30, 2022 | 0.01 |
| Mar 31, 2022 | 0.03 |
| Dec 31, 2021 | 0.04 |
| Sep 30, 2021 | 0.01 |
| Jun 30, 2021 | 0.01 |
| Mar 31, 2021 | 0.01 |
| Dec 31, 2020 | 0.01 |
| Sep 30, 2020 | 0.01 |
| Jun 30, 2020 | 0.02 |
| Mar 31, 2020 | 0.04 |
| Dec 31, 2019 | 0.04 |
| Sep 30, 2019 | 0.04 |
| Jun 30, 2019 | 0.04 |
| Mar 31, 2019 | 0.04 |
| Dec 31, 2018 | 0.04 |
| Sep 30, 2018 | 0.05 |
| Jun 30, 2018 | 0.12 |
| Mar 31, 2018 | 0.09 |
| Dec 31, 2017 | 0.12 |
| Sep 30, 2017 | 0.00 |
| Jun 30, 2017 | 0.00 |
| Dec 31, 2016 | 0.02 |
| Jun 30, 2015 | 0.01 |
| Mar 31, 2015 | 0.02 |
| Dec 31, 2014 | 0.04 |
| Jun 30, 2014 | 0.11 |
| Mar 31, 2014 | 0.18 |
| Dec 31, 2013 | 0.24 |
| Sep 30, 2013 | 0.17 |
| Jun 30, 2013 | 0.18 |
| Mar 31, 2013 | 0.25 |
| Dec 31, 2012 | 0.21 |
| Sep 30, 2012 | 0.19 |
| Jun 30, 2012 | 0.18 |
| Mar 31, 2012 | 0.18 |